Non-invasive stratification of hepatocellular carcinoma risk in non-alcoholic fatty liver using polygenic risk scores
Cristiana Bianco(Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico), Luca Valenti(University of Milan), Stefano Romeo(Sahlgrenska University Hospital), Luigi Santoro(Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico), Anna Ludovica Fracanzani(University of Milan), Umberto Vespasiani‐Gentilucci(Università Campus Bio-Medico), V. Borroni(Azienda Ospedaliera Sant’Antonio Abate di Gallarate), Elisabetta Bugianesi(University of Turin), Felix Stickel(University Hospital of Zurich), Serena Pelusi(Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico), Paola Dongiovanni(Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico), Marica Meroni(Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico), Daniele Prati(Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico), Guido Baselli(Science for Life Laboratory), Roberta D’Ambrosio(Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico), S. Maier(University of Udine), Quentin M. Anstee(Newcastle upon Tyne Hospital), Anna Alisi(Bambino Gesù Children's Hospital), Antonio Liguori(Agostino Gemelli University Polyclinic), Salvatore Petta(University of Palermo), Rocco Spagnuolo(Magna Graecia University), Jochen Hampe(Else Kröner-Fresenius-Stiftung), Helen L. Reeves(Newcastle upon Tyne Hospital), Thomas Berg(Leipzig University of Applied Sciences), Luca Miele(Agostino Gemelli University Polyclinic), Giorgio Soardo(University of Udine), Alessandro Federico(University of Campania "Luigi Vanvitelli"), Oveis Jamialahmadi(University of Gothenburg), Irene Zanoni(Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico), Janett Fischer(Leipzig University)
Cited by 361
Related Papers
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
|Hepatology|2023|2.9k
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
|Journal of Hepatology|2023|2.7k
EASL–EASD–EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)
|Journal of Hepatology|2024|1.6k